Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
Bone Marrow Endothelial Cells Regulate Myelopoiesis in Diabetes Mellitus
Friedrich Felix Hoyer1, Xinyi Zhang2,3, Emilie Coppin2
1Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Simches Research Building, Boston (F.F.H., M.J.S., D.R., C.S.A., Y.I., K.N., F.K.S., M.N.).
Insights
Diabetes mellitus disrupts bone marrow hematopoiesis by reducing Cxcl12, a factor that keeps stem cells quiet. Endothelial Egfr signaling normally curbs stem cell proliferation, but its disruption in diabetes worsens complications like delayed wound healing and atherosclerosis.
Area of Science:
- Hematology
- Endocrinology
- Vascular Biology
Background:
- Diabetes mellitus affects a significant portion of the US population, leading to severe vascular complications.
- The role of bone marrow hematopoiesis in diabetes complications is not fully understood.
- This study investigates how bone marrow endothelial cells influence inflammatory myeloid cell production in diabetes.
Purpose of the Study:
- To elucidate the role of bone marrow endothelial cells in diabetes-related hematopoiesis.
- To identify mechanisms by which diabetes dysregulates hematopoietic stem and progenitor cell (HSPC) production.
- To explore the function of endothelial Epidermal Growth Factor Receptor (Egfr) signaling in myelopoiesis.
Main Methods:
- Assayed leukocytes and HSPCs in three mouse models of diabetes (streptozotocin, high-fat diet, db/db).
- Analyzed bone marrow endothelial cells using flow cytometry and expression profiling.
- Generated mice with endothelial-specific Egfr deletion (Cdh5-Egfr) to study its functional role.
Main Results:
- Diabetes increased HSPC proliferation and circulating myeloid cells.
- Diabetic mice showed reduced endothelial Cxcl12 expression, a stem cell retention factor.
- Endothelial Egfr signaling disruption led to increased HSPC proliferation and myeloid production, exacerbating wound healing defects and atherosclerosis.
Conclusions:
- Bone marrow endothelial cells are key players in diabetes-induced hematopoiesis dysregulation.
- Diabetes impairs endothelial Cxcl12 production, promoting stem cell proliferation.
- Endothelial Egfr signaling acts as a crucial counterregulatory pathway to control HSPC proliferation and myeloid cell production in diabetes.
Background:
Diabetes mellitus is a prevalent public health problem that affects about one-third of the US population and leads to serious vascular complications with increased risk for coronary artery disease. How bone marrow hematopoiesis contributes to diabetes mellitus complications is incompletely understood. We investigated the role of bone marrow endothelial cells in diabetic regulation of inflammatory myeloid cell production.
Methods:
In 3 types of mouse diabetes mellitus, including streptozotocin, high-fat diet, and genetic induction using leptin-receptor-deficient db/db mice, we assayed leukocytes, hematopoietic stem and progenitor cells (HSPC). In addition, we investigated bone marrow endothelial cells with flow cytometry and expression profiling.
Results:
In diabetes mellitus, we observed enhanced proliferation of HSPC leading to augmented circulating myeloid cell numbers. Analysis of bone marrow niche cells revealed that endothelial cells in diabetic mice expressed less Cxcl12, a retention factor promoting HSPC quiescence. Transcriptome-wide analysis of bone marrow endothelial cells demonstrated enrichment of genes involved in epithelial growth factor receptor (Egfr) signaling in mice with diet-induced diabetes mellitus. To explore whether endothelial Egfr plays a functional role in myelopoiesis, we generated mice with endothelial-specific deletion of Egfr (Cdh5Egfr). We found enhanced HSPC proliferation and increased myeloid cell production in Cdh5Egfr mice compared with wild-type mice with diabetes mellitus. Disrupted Egfr signaling in endothelial cells decreased their expression of the HSPC retention factor angiopoietin-1. We tested the functional relevance of these findings for wound healing and atherosclerosis, both implicated in complications of diabetes mellitus. Inflammatory myeloid cells accumulated more in skin wounds of diabetic Cdh5Egfr mice, significantly delaying wound closure. Atherosclerosis was accelerated in Cdh5Egfr mice, leading to larger and more inflamed atherosclerotic lesions in the aorta.
Conclusions:
In diabetes mellitus, bone marrow endothelial cells participate in the dysregulation of bone marrow hematopoiesis. Diabetes mellitus reduces endothelial production of Cxcl12, a quiescence-promoting niche factor that reduces stem cell proliferation. We describe a previously unknown counterregulatory pathway, in which protective endothelial Egfr signaling curbs HSPC proliferation and myeloid cell production.
More Related Videos
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Regulation of Angiogenesis and Blood Supply
Production of Formed Elements
Most HSCs commit to...
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Hematopoiesis

